Franklin Biolabs CEO Selected as a 2026 Women of Influence by the Philadelphia Business Journal
Learn more

Strategies for Optimal Biomarker Selection and Validation in Early-Phase Gene Therapy Development

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Strategies for Optimal Biomarker Selection and Validation in Early-Phase Gene Therapy Development

CELL & GENE | RNA | BIOLOGICS

A robust biomarker strategy de-risks gene therapy programs and accelerates the timeline to IND. Effective programs move beyond simple transgene expression to incorporate a matrix of pharmacodynamic (PD), safety, and efficacy biomarkers. This requires developing and validating GxP-compliant bioanalytical assays that can quantitatively measure biological activity and potential immunogenicity. A well-defined framework ensures that the selected biomarkers provide clear, actionable data for dose selection, demonstrate proof-of-concept, and satisfy global regulatory expectations for safety and efficacy characterization.

    What defines a “validated” biomarker assay for a gene therapy IND?

    A: A validated assay has undergone a rigorous, documented process to confirm its performance characteristics for a specific context of use. This includes establishing accuracy, precision, specificity, sensitivity, and robustness under GxP guidelines. For gene therapies, this often involves qualifying assays for matrices like plasma, serum, or tissue homogenates.

    How do you differentiate between pharmacodynamic and safety biomarkers?

    A: Pharmacodynamic (PD) biomarkers measure target engagement and the direct biological effect of the gene therapy (e.g., restoration of protein function, reduction of a pathogenic substrate). Safety biomarkers monitor for adverse events, such as immune responses (e.g., anti-capsid antibodies for AAV vectors) or indicators of non-target tissue biodistribution effects.

    What are the primary challenges in developing biomarker assays for novel gene constructs?

    A: Key challenges include the lack of reference standards for novel proteins, potential cross-reactivity with endogenous proteins, and the low expression levels often seen with therapeutic transgenes. Developing custom reagents and highly sensitive platforms, such as ligand binding assays or LC-MS, is often necessary to overcome these hurdles.

Watch the full-length video on DIVERSIFYING THE VALUE CHAIN

A stylized 3D rendering of a DNA double helix, composed of light-colored spheres on a translucent blue backbone, set against a soft-focus, light blue background.

The Role of Biomarkers in De-Risking Gene Therapy Programs

In gene therapy development, the primary objective is to establish a clear link between vector administration, transgene expression, and a durable therapeutic effect. A strategic biomarker plan provides the quantitative evidence to build this narrative for regulators. The selection process must consider biomarkers that address multiple aspects of the therapeutic hypothesis.

This includes:

  • Vector Biodistribution & Shedding: Quantifying vector DNA to confirm delivery to target tissues and monitor clearance.

  • Transgene Expression: Measuring transgene-derived mRNA or protein to confirm functional payload delivery.

  • Target Engagement & Pharmacodynamics: Assessing the direct biological activity resulting from transgene expression.

  • Safety & Immunogenicity: Monitoring host immune responses to the vector (e.g., AAV capsid) or the transgene product.

A Framework for Biomarker Selection and Validation

An effective biomarker strategy is built on a tiered approach, aligning the analytical validation effort with the developmental stage. Early discovery may utilize non-validated research assays, but as a program advances toward IND, a transition to GxP-compliant, validated methods is required.

The strategic insights from clinical investigations inform this framework. For instance, a study on non-viral gene therapy for cystic fibrosis demonstrated how a functional biomarker (FEV1) could show a modest but significant stabilization, providing the necessary proof-of-concept for further development (PMID: 26149841). Similarly, in complex metabolic disorders like dyslipidemia, the most direct biomarkers are those measuring the intended physiological correction, such as lipid levels, which directly link the gene replacement strategy to a clinical outcome (PMID: 22505953).

A close-up of a scientist in blue gloves gently holding a small, white laboratory mouse, likely in a research setting.

GxP-Compliant Assay Lifecycle Management

Franklin Biolabs supports sponsors in developing and validating a comprehensive suite of biomarker assays within our >100,000 sq ft GxP-compliant facilities. Our approach integrates bioanalysis with our deep expertise in histology and molecular pathology to provide a complete picture of therapeutic activity and safety. This integrated strategy is a key component of our programs, which consistently achieve an 18-24 month IND timeline. Since 2019, programs managed under this scientific leadership have maintained a 100% IND success rate; the Franklin Biolabs brand itself launched in 2024.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities